X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs CIPLA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA CIPLA GSK PHARMA/
CIPLA
 
P/E (TTM) x 59.9 44.7 134.1% View Chart
P/BV x 11.7 3.7 318.9% View Chart
Dividend Yield % 2.1 0.3 602.3%  

Financials

 GSK PHARMA   CIPLA
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
CIPLA
Mar-17
GSK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs3,850622 619.1%   
Low Rs2,966458 647.1%   
Sales per share (Unadj.) Rs332.3181.9 182.7%  
Earnings per share (Unadj.) Rs44.312.9 344.2%  
Cash flow per share (Unadj.) Rs47.229.3 161.1%  
Dividends per share (Unadj.) Rs50.002.00 2,500.0%  
Dividend yield (eoy) %1.50.4 396.2%  
Book value per share (Unadj.) Rs202.7155.7 130.2%  
Shares outstanding (eoy) m84.70804.51 10.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x10.33.0 345.3%   
Avg P/E ratio x76.942.0 183.3%  
P/CF ratio (eoy) x72.218.4 391.7%  
Price / Book Value ratio x16.83.5 484.6%  
Dividend payout %112.915.5 726.3%   
Avg Mkt Cap Rs m288,643434,516 66.4%   
No. of employees `0004.623.0 20.0%   
Total wages/salary Rs m4,43426,338 16.8%   
Avg. sales/employee Rs Th6,104.56,349.1 96.1%   
Avg. wages/employee Rs Th961.61,143.0 84.1%   
Avg. net profit/employee Rs Th813.7449.3 181.1%   
INCOME DATA
Net Sales Rs m28,148146,302 19.2%  
Other income Rs m1,2182,287 53.3%   
Total revenues Rs m29,366148,589 19.8%   
Gross profit Rs m4,77424,758 19.3%  
Depreciation Rs m24813,229 1.9%   
Interest Rs m01,594 0.0%   
Profit before tax Rs m5,74412,222 47.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m260-   
Tax Rs m2,0181,798 112.3%   
Profit after tax Rs m3,75210,354 36.2%  
Gross profit margin %17.016.9 100.2%  
Effective tax rate %35.114.7 238.9%   
Net profit margin %13.37.1 188.3%  
BALANCE SHEET DATA
Current assets Rs m21,46287,370 24.6%   
Current liabilities Rs m10,53633,081 31.9%   
Net working cap to sales %38.837.1 104.6%  
Current ratio x2.02.6 77.1%  
Inventory Days Days6887 77.8%  
Debtors Days Days1662 26.3%  
Net fixed assets Rs m4,717111,567 4.2%   
Share capital Rs m8471,609 52.6%   
"Free" reserves Rs m16,308123,645 13.2%   
Net worth Rs m17,171125,254 13.7%   
Long term debt Rs m1636,454 0.0%   
Total assets Rs m30,620209,532 14.6%  
Interest coverage xNM8.7-  
Debt to equity ratio x00.3 0.3%  
Sales to assets ratio x0.90.7 131.7%   
Return on assets %12.35.7 214.9%  
Return on equity %21.98.3 264.3%  
Return on capital %33.68.5 394.9%  
Exports to sales %034.2 0.0%   
Imports to sales %15.18.3 180.5%   
Exports (fob) Rs m450,050 0.0%   
Imports (cif) Rs m4,23712,203 34.7%   
Fx inflow Rs m51951,066 1.0%   
Fx outflow Rs m8,32017,678 47.1%   
Net fx Rs m-7,80133,388 -23.4%   
CASH FLOW
From Operations Rs m1,38623,824 5.8%  
From Investments Rs m5,010-13,127 -38.2%  
From Financial Activity Rs m-6,383-13,239 48.2%  
Net Cashflow Rs m12-2,478 -0.5%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 50.7 20.8 243.8%  
Indian inst/Mut Fund % 10.2 12.2 83.6%  
FIIs % 23.8 23.7 100.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 15.4 26.2 58.8%  
Shareholders   102,036 161,166 63.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Lupin up 4%(01:30 pm)

After opening the day flat, share markets in India remained rangebound and are presently trading marginally above the dotted line.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 24, 2017 03:36 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS